ChitogenX Inc. (CHNXF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Kirkland, QC, カナダ. 現CEOは Pierre Laurin.
CHNXF を有する IPO日 2020-10-06, に上場 Other OTC, 時価総額 $627.63K.
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.
